HighTower Advisors LLC decreased its holdings in shares of IDEXX Laboratories, Inc. (NASDAQ:IDXX - Free Report) by 2.1% in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 29,832 shares of the company's stock after selling 640 shares during the quarter. HighTower Advisors LLC's holdings in IDEXX Laboratories were worth $12,334,000 at the end of the most recent quarter.
Other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. Cranbrook Wealth Management LLC grew its stake in shares of IDEXX Laboratories by 7.0% in the fourth quarter. Cranbrook Wealth Management LLC now owns 382 shares of the company's stock valued at $158,000 after buying an additional 25 shares in the last quarter. Perigon Wealth Management LLC grew its stake in shares of IDEXX Laboratories by 1.8% in the fourth quarter. Perigon Wealth Management LLC now owns 1,474 shares of the company's stock valued at $632,000 after buying an additional 26 shares in the last quarter. Summit Trail Advisors LLC grew its stake in shares of IDEXX Laboratories by 3.3% in the fourth quarter. Summit Trail Advisors LLC now owns 810 shares of the company's stock valued at $335,000 after buying an additional 26 shares in the last quarter. First Horizon Advisors Inc. grew its stake in shares of IDEXX Laboratories by 4.0% in the third quarter. First Horizon Advisors Inc. now owns 704 shares of the company's stock valued at $356,000 after buying an additional 27 shares in the last quarter. Finally, Brown Brothers Harriman & Co. grew its stake in shares of IDEXX Laboratories by 4.4% in the third quarter. Brown Brothers Harriman & Co. now owns 743 shares of the company's stock valued at $375,000 after buying an additional 31 shares in the last quarter. Institutional investors and hedge funds own 87.84% of the company's stock.
Insiders Place Their Bets
In other IDEXX Laboratories news, Director M Anne Szostak sold 3,000 shares of IDEXX Laboratories stock in a transaction dated Friday, February 7th. The stock was sold at an average price of $465.94, for a total transaction of $1,397,820.00. Following the completion of the sale, the director now directly owns 3,061 shares of the company's stock, valued at $1,426,242.34. The trade was a 49.50 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, EVP George Fennell sold 9,986 shares of the business's stock in a transaction dated Monday, February 10th. The shares were sold at an average price of $462.53, for a total value of $4,618,824.58. Following the completion of the sale, the executive vice president now directly owns 8,176 shares of the company's stock, valued at $3,781,645.28. The trade was a 54.98 % decrease in their ownership of the stock. The disclosure for this sale can be found here. 2.11% of the stock is owned by company insiders.
IDEXX Laboratories Stock Down 0.4 %
NASDAQ IDXX traded down $1.53 during trading on Thursday, reaching $420.62. 537,317 shares of the company's stock were exchanged, compared to its average volume of 549,441. The stock has a market cap of $34.21 billion, a P/E ratio of 39.42, a price-to-earnings-growth ratio of 3.41 and a beta of 1.39. The company has a debt-to-equity ratio of 0.28, a quick ratio of 0.95 and a current ratio of 1.31. The company has a 50 day moving average price of $437.54 and a two-hundred day moving average price of $445.70. IDEXX Laboratories, Inc. has a 1 year low of $398.50 and a 1 year high of $548.88.
Analyst Ratings Changes
A number of brokerages have recently weighed in on IDXX. Barclays lifted their price objective on IDEXX Laboratories from $481.00 to $520.00 and gave the company an "overweight" rating in a research note on Tuesday, February 4th. Leerink Partnrs raised IDEXX Laboratories to a "strong-buy" rating in a research note on Monday, December 2nd. StockNews.com cut IDEXX Laboratories from a "buy" rating to a "hold" rating in a research note on Saturday, March 15th. Morgan Stanley lowered their target price on IDEXX Laboratories from $559.00 to $550.00 and set an "overweight" rating for the company in a research note on Wednesday, January 29th. Finally, Bank of America boosted their target price on IDEXX Laboratories from $475.00 to $535.00 and gave the stock a "neutral" rating in a research note on Tuesday, February 4th. Four analysts have rated the stock with a hold rating, six have given a buy rating and one has assigned a strong buy rating to the company's stock. According to MarketBeat.com, the company has an average rating of "Moderate Buy" and a consensus target price of $533.75.
Read Our Latest Stock Report on IDEXX Laboratories
About IDEXX Laboratories
(
Free Report)
IDEXX Laboratories, Inc develops, manufactures, and distributes products primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets in Africa, the Asia Pacific, Canada, Europe, Latin America, and internationally. The company operates through three segments: Companion Animal Group; Water Quality Products; and Livestock, Poultry and Dairy.
See Also
Before you consider IDEXX Laboratories, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and IDEXX Laboratories wasn't on the list.
While IDEXX Laboratories currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
